Novartis Pharmaceuticals Corporation v. Cipla USA Inc. - 1:26-cv-00272

Novartis Pharmaceuticals Corporation v. Cipla USA Inc. (Case No. 1:26-cv-00272), filed on Mar 13, 2026 in the District Court, D. Delaware involving patent infringement. This case involves patent infringement claims between the parties. Explore details about the litigants, key filings, and major docket updates.

Case Details

Case Number
1:26-cv-00272
Filing Date
Mar 13, 2026
Cause of Action
Patent Infringement
Status
-
Court
District Court, D. Delaware
Nature of Suit
Patent - Abbreviated New Drug Application(ANDA)

Parties Involved

The following parties are involved in this case, with their respective legal representatives for the case.

NameRepresented By
Novartis Pharmaceuticals Corporation -
Cipla USA Inc. -

Patents Involved

This case involves 3 patents, each of which is central to the dispute. These patents may be subject to claims of infringement, challenges to their validity, or other issues concerning their scope and enforcement.

Application NumberPatent Number
-US10125369B2
-US10851377B2
-US12460206B2

Docket Entries

The Docket Entries section provides a chronological list of all significant filings and court actions in this case.

DateDocket EntryType

Set alerts for critical docket entry

Mar 13, 2026Summons Issued as to Cipla Ltd. on 3/13/2026; Cipla USA Inc. on 3/13/2026. (Attachments: # 1 Summons Issued)(scs) (Entered: 03/13/2026)PACER Document
Mar 13, 2026Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Alnylam Pharmaceuticals, Inc.. (scs) (Entered: 03/13/2026)PACER Document
Mar 13, 2026Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation, Novartis Technology LLC, The Medicines Company filed by Novartis Pharmaceuticals Corporation, Novartis Technology LLC, The Medicines Company. (scs) (Entered: 03/13/2026)PACER Document
Mar 13, 2026Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,125,369; 10,851,377; 12,460,206. (scs) (Entered: 03/13/2026)PACER Document
Mar 13, 2026Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 01/29/2026. Date of Expiration of Patent: 08/18/2034, 12/22/2035, 08/25/2036.Thirty Month Stay Deadline: 6/22/2029. (scs) (Entered: 03/13/2026)PACER Document
Mar 13, 2026Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (scs) (Entered: 03/13/2026)PACER Document
Mar 13, 2026COMPLAINT against Cipla Ltd., Cipla USA Inc. (Filing fee $ 405, receipt number ADEDC-4922280) - filed by Novartis Technology LLC, Novartis Pharmaceuticals Corporation, The Medicines Company, Alnylam Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(scs) (Entered: 03/13/2026)PACER Document
Mar 13, 2026COMPLAINT against Cipla Ltd., Cipla USA Inc. (Filing fee $ 405, receipt number ADEDC-4922280) - filed by Novartis Technology LLC, Novartis Pharmaceuticals Corporation, The Medicines Company, Alnylam Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(scs) (Entered: 03/13/2026)Attachment
Mar 13, 2026COMPLAINT against Cipla Ltd., Cipla USA Inc. (Filing fee $ 405, receipt number ADEDC-4922280) - filed by Novartis Technology LLC, Novartis Pharmaceuticals Corporation, The Medicines Company, Alnylam Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(scs) (Entered: 03/13/2026)Attachment
Mar 13, 2026COMPLAINT against Cipla Ltd., Cipla USA Inc. (Filing fee $ 405, receipt number ADEDC-4922280) - filed by Novartis Technology LLC, Novartis Pharmaceuticals Corporation, The Medicines Company, Alnylam Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(scs) (Entered: 03/13/2026)Attachment
Mar 13, 2026COMPLAINT against Cipla Ltd., Cipla USA Inc. (Filing fee $ 405, receipt number ADEDC-4922280) - filed by Novartis Technology LLC, Novartis Pharmaceuticals Corporation, The Medicines Company, Alnylam Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Civil Cover Sheet)(scs) (Entered: 03/13/2026)Attachment